Company intelligence / Profile preview

Anavex Life Sciences Corp.

Ownership: Public · AVXL
Employees: ~60
Development stage: Phase 3

Overview

Anavex's lead candidate, ANAVEX®2‑73 (blarcamesine), has shown positive results in a Phase IIb/III open-label extension trial for early Alzheimer’s disease, demonstrating significant reduction in clinical decline over three years of continuous treatment. In Rett syndrome pediatric studies, the drug showed improvement but did not reach statistical significance on all primary endpoints; however, adult studies have shown statistically significant reductions in severity. The company is also advancing ANAVEX®3‑71 into Phase 2 trials for schizophrenia and other CNS indications

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules (orally available)
Industry: Biotech

Drug pipeline

8 assets

blarcamesine

7 more assets in the full pipeline.

Request access →

Partnerships

The Michael J. Fox Foundation

Financials

Market cap: $264.1M
Total revenue: $0
Enterprise value: $145.8M

Beyond the preview

Go deeper on Anavex Life Sciences Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anavex Life Sciences Corp..

Explore the full profile